updated 5/2/2011 10:16:37 AM ET 2011-05-02T14:16:37

ATLANTA, May 2, 2011 (GLOBE NEWSWIRE) -- OTC Stock Review announces that it has initiated coverage of Celsion Corporation (Nasdaq:CLSN), a Phase III oncology focused company addressing the largest unmet need in cancer, HCC, or primary liver cancer. In our opinion, with a market cap of only $43 million, CLSN is undervalued when compared to its peers. Not only is the stock undervalued, but we believe CLSN could trade into the upper end of its trading range, and possibly make new 52 week highs, as the Company gains investor notoriety from results of its clinical trials.

CLSN has developed a technology that provides highly effective targeted delivery of chemotherapeutics. The foundation of Celsion's oncology platform is ThermoDox, a heat-sensitive liposome that Celsion has licensed from Duke University. Celsion and Duke University have developed the liposomal formulation encapsulating doxorubicin and Celsion is currently conducting ThermoDox trials for Hepatocellular Carcinoma (HCC), also referred to as primary liver cancer, and recurrent chest wall (RCW) breast cancer. ThermoDox, which represents a billion dollar global market opportunity, is in a Phase III pivotal trial with near-term commercial potential known as the HEAT Study.

Not only is the prospect of saving lives very great, but CLSN is three to four months from a planned interim analysis and approximately 12 months from top line data in an 11 country, 600 patient, global trial evaluating its first drug, ThermoDox, in the largest unmet medical need left in oncology. Our report includes a list of near-term milestones & catalysts, so investors can follow CLSN's progress.

The complete report is available at http://www.otcstockreview.com/CLSN_Review.pdf.

Additionally, more information on Celsion Corporation is available at http://www.celsion.com.

NOTE: OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. Information and opinions presented in this release are solely for informative purposes and not intended, nor should they be construed as, investment advice. This document contains information obtained from public sources about Celsion Corporation, but does not contain all the relevant material information necessary to evaluate the company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of Celsion Corporation, as profiled. Officers, directors, and employees of OTC Stock Review, hold a long equity position in Celsion Corporation and may trade in these securities for their own accounts. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm.

CONTACT: OTC Stock Review
         David Kugelman
         (866) 692-6847
         dk@otcstockreview.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 5.04%
$30K home equity loan FICO 5.23%
$75K home equity loan FICO 4.66%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.28%
13.27%
Cash Back Cards 17.74%
17.72%
Rewards Cards 17.01%
16.98%
Source: Bankrate.com